First line of biological drugs in rheumatoid arthritis: a medication persistence analysis-Reference-Cited by-同舟云学术

First line of biological drugs in rheumatoid arthritis: a medication persistence analysis

Published:2019-03-22 Issue:4 Volume:12 Page:363-370
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

dos Santos Jéssica Barreto Ribeiro¹^ORCID,Guerra Junior Augusto Afonso¹^ORCID,da Silva Michael Ruberson Ribeiro¹^ORCID,Almeida Alessandra Maciel¹^ORCID,Acurcio Francisco de Assis¹²^ORCID,Alvares-Teodoro Juliana¹^ORCID

Affiliation:

1. Department of Social Pharmacy, School of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil

2. Department of Social and Preventive Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2019.1586533

Reference34 articles.

1. Rheumatoid arthritis

2. Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry

3. Registro brasileiro de biológicos: processo de implementação e resultados preliminares do BiobadaBrasil

4. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

5. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis;Rheumatology and Therapy;2024-05-20

2. ADHERENCE AND PERSISTENCE TO TREATMENT WITH INFLIXIMAB: ANALYSIS OF A PATIENT SUPPORT PROGRAM COHORT IN BRAZIL;Arquivos de Gastroenterologia;2024

3. First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study;Sao Paulo Medical Journal;2022-12

4. Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study;Pharmacy Practice;2021-05-28

5. Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model;Expert Review of Pharmacoeconomics & Outcomes Research;2021-02-09